Jilin Joinature Polymer Co., Ltd. Overview
Jilin Joinature is China's largest producer of polyetheretherketone (PEEK), the high-performance semi-crystalline thermoplastic that replaces metal in demanding automotive, electronics, industrial, energy, medical-implant and aerospace parts. By its own account it was the world's fourth producer to reach 1,000-tonne annual PEEK capacity, after Victrex (UK), Solvay/Syensqo (Belgium) and Evonik (Germany). It was also the second producer globally, after Victrex, to polymerise PEEK in 5,000-litre reactors. In 2025 it sold more than 1,000 tonnes for the first time (1,079.84 t, +11.84%) with a design capacity of 1,000 t/y running at 102% utilisation, and it claims domestic volumes now exceed Victrex's in China. Revenue is small (CNY 309 M in FY2025). Profitability has compressed sharply because of subsidiary build-out and R&D, even as gross margin rose to 44%. The investment case now rests on a CNY 1.2 bn, 10,000 t/y PEEK plus 2,000 t/y monomer integrated complex in Zhangjiagang, Jiangsu. That project would raise capacity elevenfold into a market facing a wave of domestic capacity additions.
Company's own description (FY2024 annual report summary, paraphrased and translated)
The company describes itself as a high-tech enterprise focused on the R&D, production and sale of PEEK. It says more than a decade of in-house development has produced breakthroughs in PEEK synthesis, purification and composite reinforcement. It claims fully domestic, full-process production capability covering five areas: key raw-material selection, process control, equipment design, process optimisation and indicator monitoring. It cites an appraisal organised by the China Synthetic Resin Association concluding that its main product performance indicators reach international advanced level and fill a domestic gap, and that its industrial-scale PEEK technology leads in China.
Its products are resin-form PEEK organised as "two categories, three grades, seven series" with 89 specifications (FY2024). This expanded from 52 specifications in "six series" in earlier descriptions (Morningstar profile).
Two categories: pure resin, and composite-reinforced resin (glass fibre or carbon fibre).
Three melt-flow grades: 770, 550 and 330, from low to high flow.
Seven series: coarse powder (P), fine powder (PF), pellets (G), glass-fibre pellets (GL), carbon-fibre pellets (CA), wear-resistant pellets (FC), and application-customised products. The company also sells a small volume of finished PEEK parts.
Business model and revenue model
Revenue model: almost 100% product sales of PEEK resin and compounds, priced per tonne. There is no material service, subscription or licensing revenue. A small "PEEK products" line (finished parts, partly sourced from fabricators as samples and partly sold by the Shenzhen subsidiary) was under 2% of main-business revenue in 2023–2025 (derived from Inquiry Reply).
Pricing mechanism: at the start of each year the company sets guide prices for each grade based on cost, market conditions and strategy. These are not adjusted intra-year absent major raw-material or market shifts. Order prices are negotiated off the guide price by customer type, competitive situation, relationship history, volume and payment terms (Inquiry Reply, Q1). Rebates in kind are used: some customers stocked up in 2025 "to obtain better in-kind rebates".
Unit economics: average selling price (ASP) fell from CNY 321,900/t (2023) to CNY 287,000/t (2024) after a deliberate price cut. It was broadly stable in 2025; the derived ASP is about CNY 286,000/t on 1,079.84 t. Gross margin nonetheless rose from 39.48% (2023) to 40.08% (2024) and 44.05% (2025). The driver was cost: the main monomer, 4,4'-difluorobenzophenone (DFBP or "fluoroketone"), makes up roughly 50% of coarse-powder cost, and its purchase price fell 33.53% (2024) and 3.28% (2025). Production-line automation also lowered consumption per tonne (Inquiry Reply).
Value-chain position
Joinature sits in the polymerisation and compounding stage:
Upstream (purchased): DFBP from Zhejiang Zhongxin Fluoride Materials, Xinhan New Materials and Xingfu New Materials, plus hydroquinone, diphenyl sulfone, sodium carbonate, and carbon and glass fibres. About 0.7–0.8 t of DFBP is consumed per tonne of PEEK (Inquiry Reply).
Midstream (core): polymerisation, purification and drying into coarse powder; then grinding into fine powder, melt-filtration into pellets, or compounding into GF, CF or wear grades.
Downstream (customers): extruders, injection moulders, compression moulders and coaters who make stock shapes, film, wire, monofilament and parts.
Forward integration under way: a Shenzhen PEEK application and processing centre (parts), a Shanghai CF/PEEK composite R&D centre, and an extrusion profile line.
Backward integration planned: 2,000 t/y of PEEK monomer capacity within the Zhangjiagang project.
Customer types and end-markets
Customer types: stock-shape ("profile", 型材) extruders, which the company says are currently its largest revenue group. Others are injection moulders, compression moulders, coaters, compounders, traders and distributors, and medical-device OEMs.
Named customers and partners: BYD; Xi'an Kangtuo Medical; Weigao Orthopaedics; Dabo Medical; Guangzhou Medprin (Inquiry Reply; FY2024 annual report).
Customer concentration (Inquiry Reply, Q2): - Top-5 customer share: 43.99% (2023), 36.84% (2024), 33.34% (2025).
- Top-10 customer share: 57.97% (2023), 49.40% (2024), 50.27% (2025).
End-markets cited by the company: automotive and transport (including NEV motor enamelled wire and battery seals), electronics and semiconductors (CMP retaining rings, wafer carriers, phone fixtures, speaker diaphragms), industrial machinery and energy (seals, compressor valve plates, bearings), medical implants, aerospace, humanoid robots and the low-altitude economy, and 3D printing (Longbridge profile; FY2024 AR; Inquiry Reply).
Independent characterisation
Joinature is best understood as a single-polymer, sub-scale specialty-chemicals manufacturer that has won the Chinese industrial-grade PEEK market on cost and availability. It is now trying to move up-mix (medical, semiconductor, aerospace) and up-scale (10 kt) simultaneously.
Strengths: a decade-plus of process know-how, a proven 5,000 L reactor process, high utilisation and rising gross margins.
Weaknesses: its customer base is still dominated by price-sensitive stock-shape extruders. Its premium-segment penetration (medical-implant revenue was only CNY 5.17 M cumulatively over 2023–2025) is embryonic. Its overseas share is below 1%.
Profit trend: reported profitability has collapsed from CNY 54.6 M (2023) to CNY 11.9 M (2025) and a CNY 13.0 M loss in H1 2026, as operating expenses scale ahead of revenue.
Investment profile: the business is effectively a capacity-expansion option on Chinese PEEK demand, funded largely by IPO cash and prospective bank debt.
Strategy
Stated strategy themes (FY2024/FY2025 annual reports; Inquiry Reply)
"Full industrial chain, high-end, scale" (全产业链、高端化、规模化): the stated medium- to long-term strategy. It means integrating backward into monomer, scaling to 10 kt+, and shifting the mix to medical, semiconductor and aerospace grades.
Import substitution and "plastic replacing steel": capturing China's roughly 1,100 t/y of PEEK imports (2024) and metal-replacement demand.
Application-led growth: opening new end-uses such as NEV 800 V motor wire, humanoid robots, the low-altitude economy, 3D printing and hydrogen equipment.
"Quality, efficiency, returns" action plan (提质增效重回报): sustained cash dividends and investor communication (H1 2025 board notice; FY2025 AR).
Medical focus for margin: management says the downstream layout will favour medical "from a gross-margin perspective", while stock-shape customers dominate revenue today (CLS, May 2026).
Initiative register (last 24 months)
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Jul 2024 | Shanghai CF/PEEK composite R&D centre (new subsidiary) | Relocated and re-scoped IPO project | Completed |
| 2,024 | Shenzhen PEEK application and processing centre | Downstream fabrication and application support | Operating; loss-making |
| Jun 2024 | PEEK-LISCIEX medical master file | NMPA registration M2024156-000 | Six devices registered using the material |
| Jul 2024 | Medical R&D capitalisation begins | CNY 2.52 M (2024), CNY 5.40 M (2025) capitalised | Ongoing; project end Jun 2028 |
| 2024–2025 | Production-line automation upgrade | Lower unit consumption, better batch consistency | Completed (cited for 2025 cost decline) |
| 2,025 | European expansion | DQS audit, European warehouse, new EU and Taiwan customers | In progress |
| 2,025 | Humanoid-robot PEEK parts R&D | CNY 3.52 M spent in 2025 | Partial adoption |
| 2,025 | Monomer localisation pilot (合成聚芳醚酮原料国产化中试) and "F4422" project | CNY 10.78 M and CNY 5.19 M R&D in 2025; aimed at self-supply of key raw materials | Lab-to-pilot scale-up |
| Apr 2026 | K.D. Feddersen European distribution | ZyPEEK across Europe | Active |
| 28 Apr 2026 | Private placement to chairman (≤CNY 303 M for working capital) | Priced at CNY 26.35 | Terminated 17 Jul 2026 |
| 14 May 2026 | Zhangjiagang 10 kt PEEK plus 2 kt monomer project | Total ≈ CNY 1,157.6 M (preliminary): construction CNY 970.8 M, capitalised interest CNY 54.0 M, working capital CNY 132.8 M | Pre-approval; subsidiary formed Jul 2026 |
| 30 Jul 2026 | Share buyback | CNY 50–100 M at ≤CNY 48.94; 3 months; up to CNY 90 M bank-loan backed | In progress (no progress report verified) |
Medium-term targets and guidance
No formal revenue or profit guidance: A-share STAR companies rarely publish it.
Capacity target: 11,000 t/y total (1,000 existing plus 10,000 new), phased over 2–4 years.
Funding plan: about CNY 510 M of new long-term bank debt. Pro-forma liabilities/assets would rise to about 35% (about 30% had the placement proceeded). Assumed interest is about CNY 17.85 M per year (2027–2029), capitalised during construction (Inquiry Reply Q7).
Post-completion fixed-cost burden: about CNY 66.5 M per year of depreciation plus CNY 2.1 M of amortisation, about 22% of FY2025 revenue.
Quality ambition: product purity and batch consistency to "catch up with and surpass" Victrex.
Products & Services
All products are sold under the ZyPEEK brand. Grades are built on three base melt-flow families: 770 (low flow, high toughness, the flagship "770G" pellet), 550 (medium) and 330 (high flow, for thin-wall injection). Specific pricing is not publicly disclosed. The group ASP was about CNY 287,000/t in 2024 (Inquiry Reply).
Pure resin category
| Product series | Description | Key properties / processing | Target customers & uses | Status / notes |
|---|---|---|---|---|
| Coarse powder (P series) | First-stage product after polymerisation, purification and drying | Feedstock for all other series; can be melt-filtered, ground or compounded | Compounders and some processors; mostly consumed internally | External sales curtailed in 2025 (CNY 11.55 M revenue) |
| Fine powder (PF series), incl. ultra-fine powder | Ground coarse powder | Compression moulding; powder and water-based coatings | Compression moulders and coaters: seal rings, gaskets, gears; chemical pipe linings, bearing cages, non-stick cookware coatings, textile rollers, food moulds | Fastest growing in 2025 (+38%); highest pure-resin margin (54%); "ultra-fine" grades noted as high-growth (FY2025 AR) |
| Pellets (G series), flagship 770G | Melt-extruded and melt-filtered coarse powder | Uniform pellets, low gel, low impurities; extrusion and injection | Extruders and moulders: monofilament, cable, film, stock shapes; phone-manufacturing fixtures, earphone diaphragms, gears, instrument tubing, cable clips | Core product (CNY 180.9 M, 2025) |
Composite-reinforced category
| Product series | Description | Key properties | Uses | Status |
|---|---|---|---|---|
| Glass-fibre reinforced (GL series) | PEEK plus glass fibre | High strength and toughness | Compressor valve plates, piston rings, seal rings, chemical pump bodies, valves | Within composite revenue (CNY 86.4 M, 2025) |
| Carbon-fibre reinforced (CA series) | PEEK plus selected carbon fibre | High strength, wear resistance, thermal conductivity | Auto functional parts (gaskets, pumps, transmission parts, bearings, valve plates), HV/LV electrical parts, chemical containers, pipes, valves; compressor, textile and medical parts | Same |
| Wear-resistant (FC series) | PEEK plus CF, PTFE and graphite | Self-lubricating, very high wear resistance, slightly lower strength than CA | Bearings and bushes | Same |
Application-customised series (FY2024 AR)
| Product | Description / target | Status |
|---|---|---|
| Ceramic-modified PEEK | Specialty compound | Commercial (scale not disclosed) |
| Consumer-electronics grades | For phone and earphone components, fixtures | Commercial |
| Wafer-carrier grades | Semiconductor wafer handling | Generation-one wafer-box and anti-static products in pilot stage (Inquiry Reply Q5) |
| Anti-static profile grades | ESD-safe stock shapes for electronics and semiconductors | Pilot / early commercial |
| Coloured PEEK | Pigmented grades | Commercial |
| PEEK-LISCIEX implant-grade PEEK | Medical implant grades (ZR3G, ZR7G, ZR7) made in a 1,140.72 m² Class-10,000 GMP clean workshop with ISO 13485 certification | NMPA master file registered Jun 2024. Six registered medical devices use the material; small-batch shipments began H2 2025. Cumulative 2023–2025 revenue CNY 5.17 M. Implant-grade 3D-printing filament and short-CF-reinforced grades are close to completing biocompatibility evaluation (Inquiry Reply Q5; GTJA HK) |
| Radiation-resistant PEEK | For nuclear-power coils and windings | Mass production; passed irradiation testing; cumulative 2023–2025 revenue CNY 28.92 M |
PEEK products (fabricated parts) and new platforms
| Offering | Description | Status |
|---|---|---|
| Fabricated PEEK parts (Shenzhen) | Injection-moulded, extruded and machined parts | Capable of most standard parts; 2025 margin 5.17% |
| PEEK stock-shape extrusion line | Profiles (rod, plate) | Line built (Inquiry Reply Q5) |
| PAEK pilot line | Polyaryletherketone for aerospace | Pilot line built; small-batch trial production |
| CF/PEEK unidirectional prepreg | Continuous carbon-fibre composite tape for aerospace and orthopaedics | Trial production; company was lead drafter of a related group standard |
| Humanoid-robot PEEK parts | Joint and reducer components | "Some applications successfully introduced", others in co-development |
Financial Narrative
All figures are CNY M under PRC Accounting Standards (CAS), consolidated, audited annual figures. Sources: cfi.cn financial-indicator pages (republished filings); FY2024 flash results (STCN, 26 Feb 2025); FY2024 AR summary; Inquiry Reply; IPO prospectus data via Jiemian and Chinabaogao.
Income statement
Notes: - FY2023 revenue is derived from FY2024 revenue of CNY 277 M (−5.05% YoY) and agrees with R&D/revenue of 7.91%. FY2023 COGS and gross profit are derived from the 39.48% gross margin.
-
FY2023 pre-tax and net profit are derived from the FY2024 flash (pre-tax −27.74%, net −27.99%). cfi.cn shows FY2023 net profit as CNY 0.55 bn rounded.
-
FY2022 net profit is CNY 0.56 bn rounded (cfi.cn). FY2021 deducted net profit of CNY 47.18 M is from the prospectus (Jiemian).
-
FY2024 EPS is derived (39.29 / 121.68 M shares).
Margins and growth
Revenue CAGR FY2021–FY2025: 11.1% (derived; 203.0 → 309.2). FY2019–FY2022 revenue was CNY 112 M, 158.2 M, 203.0 M and 248.1 M (prospectus via Jiemian and Chinabaogao).
Quarterly trajectory (most recent six quarters)
Derived from cumulative cfi.cn figures (H1 2025 revenue 131.28 / NP 7.03; 9M 2025 207.03 / 10.43; FY2025 309.22 / 11.87; Q1 2026 65.63 / −4.81; H1 2026 131.66 / −12.96). Q1 2025 net profit is derived from the disclosed −185.04% YoY decline in Q1 2026.
Balance sheet
Sources: cfi.cn (FY2025 balances); cfi.cn quote page (net assets 2022–2025); Inquiry Reply Q1 and Q6 (inventory, prepayments). FY2024 prepayments are derived from the FY2025 balance of CNY 17.11 M (+101.19%).
Debt. The company does not break out total borrowings in the sources retrieved.
-
At end-2025, bank credit facilities totalled CNY 682.0 M, of which CNY 119.27 M was drawn. This included a CNY 37.0 M fixed-asset loan; the balance is likely trade-finance instruments (Inquiry Reply Q7).
-
FY2025 financing cash inflow was CNY 55.6 M, indicating new borrowing.
-
At end-2025, gross cash plus short-term wealth products comfortably exceeded borrowings, so net cash was large and positive (estimated > CNY 400 M at end-Q1 2026).
-
Goodwill: none (no acquisitions). Intangibles include capitalised medical-PEEK development of CNY 2.52 M (2024) and CNY 5.40 M (2025).
Cash flow
Note: Gross investing flows are inflated by rolling wealth-management products (FY2025 inflows CNY 4.35 bn, outflows CNY 4.56 bn). Pure capex and free cash flow are not separately verified.
Management explains the negative FY2025 operating cash flow by heavy use of bills: bank acceptance bills received, endorsed and discounted are excluded from operating cash flow under its policy. It says operating cash flow "adjusted" for these would be positive, and that Q1 2026 OCF turned positive (Investor Q&A, fxbaogao). Analysts should treat this with caution, because H1 2026 OCF was again negative (−CNY 16.0 M).
Key ratios
Derived. FY2023 ROE is depressed by IPO equity arriving in September (average-equity basis). The FY2024 payout ratio is disclosed (61.95%). The FY2025 payout (CNY 24.34 M ÷ CNY 11.87 M) is derived.
Not computable from verified data: ROIC, current ratio, net debt/EBITDA, interest coverage, cash conversion cycle and EBITDA. Depreciation is not disclosed in the retrieved sources. Interest expense is immaterial given the net-cash position.
Commentary — trends, inflections, drivers
-
Growth phase (2019–2023). Revenue rose from CNY 112 M to about CNY 292 M (≈27% CAGR) as China adopted domestic PEEK and Joinature scaled toward 1,000 t. Margins were healthy: net margins of about 19–23%.
-
Price-for-volume inflection (2024). Facing "intensifying domestic competition and international political-economic changes", management cut prices about 11% (ASP CNY 321.9k → 287.0k/t). Revenue fell 5%. Gross margin still edged up because DFBP costs fell 34%, but net profit fell 28% as opex rose with the IPO-funded expansion.
-
Volume recovery with profit collapse (2025). Volume rose 11.84% to 1,079.84 t and revenue rose 11.6%. Gross margin rose to 44.05%. However, opex growth overwhelmed gross profit:
-
Total operating cost rose to CNY 302.0 M (97.7% of revenue).
-
R&D investment jumped 48% to CNY 47.2 M.
-
Shanghai and Shenzhen subsidiaries ran losses.
-
Spending on HR systems, brand, digitalisation and lean management increased (GTJA HK).
-
Net profit fell 70%.
-
-
Losses (H1 2026). Revenue was flat at CNY 131.7 M even as gross margin rose to 50.64% in Q1 2026. The company lost CNY 13.0 M as subsidiary headcount (hired from Q2 2025) burdened costs without matching revenue. The key inflection to monitor is whether revenue growth resumes before the Zhangjiagang capex cycle adds about CNY 68.6 M per year of depreciation and amortisation.
-
Balance-sheet quality. Leverage is very low (liabilities about 10.5% of assets). The company carries no goodwill and no inventory write-downs. The SSE challenged the absence of write-downs given inventory turnover of about 1.1–1.4x; management defended it on high margins and long shelf life. Semi-finished inventory nearly tripled from 2023 to 2025 (CNY 18.3 M → 50.8 M).
-
Capital allocation tension. The company paid more in dividends (CNY 24.3 M) than it earned in FY2025, is buying back stock (CNY 50–100 M, partly bank-funded), and plans about CNY 510 M of new debt for the 10 kt project. Those three commitments compete for the same cash pile.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Location | Role | Status / notes | Source |
|---|---|---|---|---|
Jilin Joinature Polymer Co., Ltd. (parent) | Changchun, Jilin | Polymerisation, compounding, sales, medical GMP workshop | Parent-only FY2025 revenue CNY 306.64 M; net profit CNY 52.08 M | Inquiry Reply Q1 |
Zhongyan Composites (Shanghai) Technology Development Co. ("中研上海") | Shanghai | Carbon-fibre/PEEK composite R&D centre (IPO project) | Established 2024; loss-making start-up phase; centre completed | Board notice Jul 2024; CLS |
Zhongyan Shenzhen ("中研深圳") | Shenzhen, Guangdong | PEEK application and processing centre; small parts sales | Established 2024; loss-making start-up phase | Inquiry Reply Q1; GTJA HK note |
Zhongyan Top Polymer Materials (Jiangsu) Co. ("中研拓普") | Zhangjiagang, Jiangsu | Vehicle for 10 kt PEEK plus 2 kt monomer project | Approved 17 Jul 2026; CNY 100 M registered capital | CLS 17 Jul 2026 |
Houhe Medical device R&D centre ("厚和医疗器械研发中心") | Not specified | Medical-device R&D (IPO project) | In construction; part of remaining CNY 104 M IPO spend | Inquiry Reply Q7 |
Revenue by Segment
| Product category (CNY Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Pure resin – total | 211.59 | 196.44 | 216.54 |
Pure resin – pellets (G) | 170.18 | 151.56 | 180.87 |
Pure resin – fine powder (PF) | 20.05 | 17.43 | 24.12 |
Pure resin – coarse powder (P) | 21.36 | 27.46 | 11.55 |
Composite-reinforced (GL/CA/FC) | 78.46 | 76.77 | 86.38 |
PEEK products (derived residual) | 1.80 | 3.89 | 6.29 |
Main-business revenue (derived) | 291.85 | 277.10 | 309.21 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGross margin (%)
| Gross margin (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Pure resin pellets | 37.61 | 34.56 | 39.37 |
Pure resin fine powder | 44.88 | 50.03 | 53.96 |
Pure resin coarse powder | 33.36 | 42.12 | 48.41 |
Composite-reinforced | 43.28 | 47.19 | 53.35 |
PEEK products | — | 56.07 | 5.17 |
Company gross margin | 39.48 | 40.08 | 44.05 |
Share of main-business revenue (%)
| Share of main-business revenue (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Pure resin | 72.50 | 70.89 | 70.03 |
Composite-reinforced | 26.89 | 27.71 | 27.93 |
PEEK products | 0.61 | 1.40 | 2.04 |
YoY growth (%)
| YoY growth (%) | FY2024 | FY2025 |
|---|---|---|
Pellets | -10.94 | 19.34 |
Fine powder | -13.09 | 38.38 |
Coarse powder | 28.57 | -57.94 |
Composite-reinforced | -2.15 | 12.52 |
Sell-through ratio (%)
| Sell-through ratio (%) | FY2024 | FY2025 | Q1 2026 |
|---|---|---|---|
Pure resin pellets | 95.60 | 112.10 | 45.89 |
Composite-reinforced | 90.66 | 84.91 | 83.39 |
Pure resin fine powder | 71.75 | 82.91 | 97.59 |
Pure resin coarse powder (external) | 9.00 | 4.17 | 0.69 |
Income Statement and Per-Share Data
| Metric (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 203.0 | 248.1 | 291.9 | 277.0 | 309.2 |
Cost of revenue | — | — | 176.7 | 166.0 | 173.0 |
Gross profit | — | — | 115.2 | 111.0 | 136.2 |
Operating profit | — | — | — | — | 17.2 |
Pre-tax profit | — | — | 60.0 | 43.4 | 15.9 |
Net profit attributable | — | 56.0 | 54.6 | 39.3 | 11.9 |
Net profit excl. non-recurring items | 47.2 | — | 41.0 | 24.6 | 4.9 |
Non-recurring items | — | — | — | 14.7 | 7.0 |
R&D investment (expensed + capitalised) | — | — | 23.1 | 31.9 | 47.2 |
Basic EPS (CNY) | — | — | — | 0.32 | 0.10 |
Diluted EPS (CNY) | — | — | — | 0.32 | 0.10 |
Dividend per share (CNY) | — | — | 0.20 | 0.20 | 0.20 |
Margin Analysis (%)
| Ratio (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth | 28.3 | 22.2 | 17.7 | -5.1 | 11.6 |
Gross margin | — | — | 39.48 | 40.08 | 44.05 |
Operating margin | — | — | — | — | 5.6 |
Pre-tax margin | — | — | 20.6 | 15.7 | 5.1 |
Net margin | — | 22.6 | 18.7 | 14.2 | 3.8 |
R&D / revenue | — | — | 7.91 | 11.52 | 15.25 |
Income Statement
| Metric (CNY Mn) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Revenue | 64.56 | 66.72 | 75.75 | 102.19 | 65.63 | 66.03 |
Net profit attributable | 5.66 | 1.37 | 3.40 | 1.44 | -4.81 | -8.15 |
Balance Sheet
| Metric (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets | — | — | — | 1,338.2 |
Total liabilities | — | — | — | 154.2 |
Shareholders' equity | 327.0 | 1,157.0 | 1,172.0 | 1,184.0 |
Cash & cash equivalents (year-end) | — | — | — | 331.6 |
Inventory – raw materials | — | 101.4 | 58.8 | 57.7 |
Inventory – self-made semi-finished | — | 18.3 | 41.5 | 50.8 |
Prepayments | — | — | 8.5 | 17.1 |
Share capital | — | 121.68 | 121.68 | 121.68 |
Capital reserve | — | — | — | 887.4 |
Retained earnings | — | — | — | 143.1 |
Balance Sheet and Margin Analysis (%)
| Metric (CNY Mn) | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|
Total assets | 1,302.1 | 1,281.9 |
Total liabilities | 122.9 | 135.1 |
Equity | 1,179.2 | 1,146.7 |
Cash & cash equivalents | 349.6 | 243.7 |
Trading financial assets (structured deposits / wealth products) | 175.0 | — |
Liabilities / assets (%) | 9.44 | 10.54 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric (CNY Mn) | FY2024 | FY2025 |
|---|---|---|
Operating cash flow | — | -37.7 |
Investing cash flow | — | -211.3 |
Financing cash flow | — | 28.4 |
Dividends paid (for prior year) | 24.3 | 24.3 |
Share buybacks | 0 | 0 |
Cash Flow (9M 2025–H1 2026)
| Metric (CNY Mn) | 9M 2025 | Q1 2026 | H1 2026 |
|---|---|---|---|
Operating cash flow | -56.7 | 1.3 | -16.0 |
Investing cash flow | -94.6 | -21.1 | -59.9 |
Financing cash flow | 24.2 | -0.2 | -12.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE (%) | 7.4 | 3.4 | 1.0 |
ROA (%) | — | — | 0.9 |
Inventory turnover (x) | 1.41 | 1.09 | 1.21 |
Liabilities / assets (%) | — | — | 11.5 |
Dividend payout (%) | 44.6 | 61.95 | 205.0 |
Region (H1 2024) Overview
| Region (H1 2024) | Revenue (CNY Mn) | Share (%) | Gross margin (%) |
|---|---|---|---|
Mainland China | 129.0 | 96.3 | 40.15 |
Overseas | 5.0 | 3.7 | 40.42 |
Share Price History
| Date | Price | Comment | Source |
|---|---|---|---|
20 Sep 2023 | 29.66 | IPO price | IPO notice |
25 Apr 2025 | 37.31 | Market cap CNY 4.54 bn; P/E (TTM) 101x | Moomoo |
28 May 2025 | 35.98 | Market cap ≈ EUR 368 M; P/E 112.6x | finanzen.net |
Late Jun 2026 | 36.57 | +10.18% session | cfi.cn |
24 Jul 2026 | 24.70 | 20-day fall ≥20%; below 50% of 1-year high close (implying a 1-year high close above CNY 49.4) | Buyback notice |
10 Aug 2026 | 29.08 | 1-year return −25.95% | Disfold |
Share Price & Returns
| Period | Return | Basis |
|---|---|---|
Since IPO (to 10 Aug 2026) | -2.0% | 29.08 vs 29.66 (derived) |
1-year (to 10 Aug 2026) | -25.95% | Disfold |
Annualised since listing | -5.07% | Lixinger (mid-2026) |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | ≈CNY 3.54 bn | 121.68 M shares |
P/E (FY2025) | ≈291x | EPS CNY 0.10 |
P/E (TTM to H1 2026) | Negative | TTM NP ≈ −CNY 8.1 M (derived) |
P/B | ≈3.1x | Equity CNY 1,146.7 M (30 Jun 2026) |
EV / Sales (FY2025) | ≈9.7x | EV ≈ CNY 3.0 bn after ≈CNY 0.5 bn net cash (approximate) |
EV / EBITDA | Not computable | EBITDA not disclosed |
Dividend yield | ≈0.7% | CNY 0.20 / 29.08 |
Analyst Ratings & Targets
| Date | Broker | Rating | Theme |
|---|---|---|---|
14 Sep 2025 | Huajin Securities | Buy | Initiation: domestic PEEK leader, import substitution |
14 Oct 2025 | Everbright Securities | Accumulate | 10 kt integrated project |
17 May 2026 | Everbright Securities | Accumulate | Project signing |
27 Jun 2026 | Guotai Junan International (HK) / "Global Fortune" | No rating shown | FY2025 review |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
DPS (CNY) | 0.20 | 0.20 | 0.20 |
Total payout (CNY Mn) | 24.34 | 24.34 | 24.34 |
Payout ratio (%) | 44.6 | 61.95 | 205.0 |
Analyst Conclusions
Management guidance
-
No numeric guidance.
-
Qualitative statements:
-
Commitment to new applications and faster order release (IR, 30 Sep 2026).
-
Phased build of Zhangjiagang over 2–4 years.
-
Expected short-term earnings pressure from depreciation and qualification lags, with long-term margin gains from monomer self-supply and mix upgrade (Inquiry Reply Q7).
-
Consensus growth expectations
No published consensus is available. Industry forecasts imply Chinese PEEK market growth of about 17.8% per year (2025–2030). Joinature's realised volume growth was +11.8% in 2025 and about 0% in H1 2026 (revenue basis).
Bull case
-
Capacity-constrained leader in a fast-growing market. Utilisation was 102% and coarse powder was rationed internally, so flat H1 2026 revenue partly reflects a supply ceiling. Phase II deep-processing capacity (from Sep 2026) and the first Zhangjiagang phase could unlock volume into China's demand, which grew at a 38% CAGR over 2012–2024.
-
Structural margin upside from integration. Gross margin already reached 50.6% in Q1 2026. Self-made monomer, about 50% of PEEK cost, plus scale could make Joinature the global cost leader while Victrex's Panjin plant struggles at about 3% utilisation.
-
Optionality in premium niches. Six registered medical devices, a GMP plant and capitalised medical R&D position the company for orthopaedic volume-based procurement, where domestic materials gain share. Each 1% shift of China's medical PEEK into its grades carries outsized margin. Net cash of about CNY 0.4–0.5 bn funds the early phases without dilution.
Bear case
-
Commoditisation ahead. 38,300 t/y of announced capacity, including a 12,000 t/y entrant (Ningbo Huaxiang) and an 8,000 t/y DFBP supplier moving downstream (Xinhan), dwarfs 2026E Chinese demand of 4,358 t. Customers are already building in-house capacity. The 2024 price cut may be a preview.
-
Operating de-leverage. Opex is already about 98% of revenue. The 10 kt project adds about CNY 68.6 M per year of depreciation and amortisation and about CNY 17.9 M per year of interest (capitalised only during construction). Without revenue doubling, losses widen through 2027–2029 and impairments become plausible.
-
Governance and capital-allocation signals. Dividends exceeded earnings, a debt-funded buyback runs alongside an acting-CFO share sale, the controller's placement was withdrawn, auditors changed three times, and the SSE questioned customer quality. Together these suggest weak capital discipline at a moment of maximum capex.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable | Why it matters |
|---|---|---|
| By 31 Oct 2026 | Q3 2026 results | Whether revenue re-accelerates and losses narrow |
| ≈30 Oct 2026 | Buyback completion amount | Delivery vs the CNY 50 M floor |
| Q4 2026 | Phase II deep-processing plant commissioning | Volume capacity vs depreciation onset |
| Q4 2026 – H1 2027 | Zhangjiagang approvals (filing, EIA, hazardous-process review) and first loan drawdowns | Project feasibility and leverage path |
| ≈Sep 2026 – Mar 2027 | Controller lock-up expiry (36 months, possibly extended 6 months) | Share overhang |
| Ongoing | ASP trend and DFBP prices | Margin sustainability |
| Ongoing | Medical and semiconductor revenue disclosure | Mix-upgrade proof points |
| 2,027 | FY2026 annual report; auditor continuity | Governance signal |
| Ongoing | Competitor ramp-ups (Victrex Panjin, Pengfulong, Junhua, Xinhan, Huaxiang) | Pricing environment |
Analyst verdict
Jilin Joinature is a technically credible, strategically important but financially fragile company. Operationally it has done what a Chinese specialty-materials champion should:
-
It mastered a polymer long under Western export control.
-
It wrote the national standard.
-
It reached 1,000 t/y and ran its plant above nameplate.
-
It lifted gross margin to the mid-40s and then about 50% even after cutting prices.
Its disclosures in the June 2026 Inquiry Reply are unusually candid and show a management team that understands the capacity race it has entered.
The equity, however, prices in success that the financials do not yet support. At about CNY 29 per share the company trades near 10x sales, roughly 3x book and hundreds of times FY2025 earnings, while it is now loss-making. Revenue growth stalled in H1 2026 and operating cash flow is negative. The strategic response is to multiply capacity elevenfold with about CNY 1.2 bn of spending, roughly CNY 510 M of it borrowed. It does so into an industry where announced additions already approach 40,000 t/y against a Chinese market of about 4,000 t.
History favours incumbents with process know-how: Victrex's own China plant produced only 50 t in its first year. That gives Joinature a real but time-limited advantage. The decisive variables over the next 12–24 months are three: whether revenue resumes double-digit growth as Phase II capacity arrives, whether the medical and semiconductor grades turn from pilot sales into tens of millions of revenue, and whether governance stabilises around permanent finance leadership and consistent capital allocation.
Verdict: Neutral / high-risk. It is a strategically well-positioned asset with an attractive long-term thesis on Chinese PEEK import substitution and monomer integration, but near-term earnings, cash flow and governance signals argue for waiting for evidence of profitable volume growth before underwriting the 10 kt expansion. A more constructive stance would be warranted on two quarters of revenue growth above 15% with positive operating cash flow, or on a material de-rating toward 1.5–2x book.
Data current to filings published through early October 2026. The live share price for 7 Oct 2026, FY2025 executive compensation, the controllers' exact shareholdings, full-year geographic splits, capex and EBITDA were not verifiable from retrievable primary sources and are marked accordingly.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Notes | Source |
|---|---|---|---|
Xie Huaijie (谢怀杰) | Chairman; legal representative and "person in charge" | Co-actual controller. Was proposed subscriber in the terminated 2026 private placement. Third-party aggregators list him as CEO (Simply Wall St shows "Huajie Xie"). | Board notices; Q1 2025 report |
Yang Liping (杨丽萍) | Non-independent director; acting CFO (代财务总监), head of accounting | Holds 600,700 shares (0.49%). Announced a share-sale plan for 3 Aug–2 Nov 2026. | Q1 2025 report; buyback notice |
Bi Xin (毕鑫) | Non-independent director | Co-actual controller | Board notice Jul 2024; Lixinger |
Xie Yuning (谢雨凝) | Non-independent director | Co-actual controller; represented the company at the Zhangjiagang signing | Xinhua Finance |
Li Zhenfang (李振芳) | Non-independent director | Former officer at IPO; lock-up extended then released Mar 2025 | Notice 2025-003 |
Gao Fang (高芳) | Non-independent director | IPO-era board secretary / contact person | IPO notice; Notice 2025-003 |
An Yaren (安亚人) | Independent director | — | Board notice Jul 2024 |
Su Zhiyong (苏志勇) | Independent director | — | Board notice Jul 2024 |
Zhou Baicheng (周佰成) | Independent director | — | Board notice Jul 2024 |
Executive Leadership Team
| Name | Role | Notes |
|---|---|---|
Xie Huaijie | Chairman / principal executive | See above |
Yang Liping | Acting CFO | The "acting" designation indicates the CFO post has not been permanently filled |
Wang Mingzhuo (王明卓) | Head of accounting department | Q1 2025 report |
New board secretary | Appointed 17 Jul 2026 | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Jul 2024 | Fourth board elected (6 non-independent, 3 independent) | Scheduled expiry of third board on 12 Jul 2024 |
17 Jul 2026 | New board secretary appointed | Same meeting terminated the controller's private placement |
Ongoing | Acting CFO arrangement (Yang Liping) | Permanent CFO not named |
Major Shareholders
| Rank | Holder | Shares | % of total |
|---|---|---|---|
| 1 | Liu Guoliang (刘国梁) | 2,805,050 | 2.31 |
| 2 | Wang Xiuyun (王秀云) | 2,607,300 | 2.14 |
| 3 | Haitong Innovation Securities Investment Co. (sponsor co-investment vehicle) | 1,318,617 | 1.08 |
| 4 | Guotai Jiatai equity pension product – China Merchants Bank | 1,071,302 | 0.88 |
| 5 | Yang Liping (director, acting CFO) | 600,700 | 0.49 |
| 6 | Chen Zhanhui (陈展辉) | 547,143 | 0.45 |
| 7 | Jing Tao (荆涛) | 525,058 | 0.43 |
| 8 | Wang Yanlong (王彦龙) | 465,681 | 0.38 |
| 9 | Yang Jun (杨军) | 456,834 | 0.38 |
| 10 | Changchun Science & Technology Venture Capital Co. | 449,870 | 0.37 |
Competitive Landscape
Key Competitors
| Company | Country | Existing PEEK capacity (t/y) | Planned (t/y) | Positioning |
|---|---|---|---|---|
Victrex plc (VCT.L) | UK (+ China JV) | 7,150 | — | Global leader and PEEK inventor; Invibio medical; aerospace, auto, electronics |
Victrex Panjin (JV with Yingkou Xingfu) | China (Liaoning) | 1,500 | — | China-for-China plant; produced ≈50 t in FY2025 (Sep YE) |
Syensqo (ex-Solvay Specialty Polymers; KetaSpire) | Belgium / India | 2,500 | — | High-temperature, chemical resistance; oil and gas, electronics |
Evonik (VESTAKEEP) | Germany / China | 1,800 | — | Low moisture uptake; strong in medical implants |
Zhejiang Pengfulong (鹏孚隆) | China | 1,500 (design) | — | Domestic challenger |
Junhua Co. / Shandong Junhao (君华股份/山东君昊) | China | 1,500 (design) | 1,100 | Domestic challenger |
Jilin Juke High-Tech (吉林聚科高新) | China | 700 | 1,000 | Changchun neighbour |
Changchun Jida Special Plastics (长春吉大特塑) | China | 500 | — | Jilin University spin-off lineage |
Wote Advanced Materials (沃特股份, 002886.SZ) | China | 500 | 500 | Diversified specialty polymers (>CNY 2 bn revenue) |
Kingfa Sci & Tech (金发科技, 600143.SH) | China | 400 | — | Compounding giant |
Shandong Haoran Special Plastics | China | 300 | — | Small producer |
Xinhan New Materials (新瀚新材) | China | 200 | 8,000 | Also a DFBP supplier; moving downstream |
Mitsubishi Chemical | China (Changshu) | — | 600 | Entrant |
Ningbo Huaxiang (宁波华翔) | China | — | 12,000 | Auto-parts group entering PEEK |
Guoen (国恩股份) | China | — | 1,000 | Entrant |
Huitong (会通股份) | China (Shanghai) | — | 600 | CNY 81 M high-temperature nylon plus PEEK polymerisation project (Oct 2025) |
Baihehua (百合花), Dayang Bio (大洋生物), Jilin Yihong | China | — | 1,000 / 2,000 / 500 | Entrants |
Jilin Joinature | China | 1,000 | 10,000 | Domestic volume leader |
Total (company's table) | — | 19,550 | 38,300 | — |
Peer Comparison FY2025
| Metric | Jilin Joinature (FY2025, Dec YE) | Victrex (FY2025, Sep YE) | Wote Advanced Materials (FY2025) | Haohua Technology (FY2025) |
|---|---|---|---|---|
Revenue | CNY 309.2 M | GBP 292.7 M (≈CNY 2.8 bn) |
|
|
Revenue growth | +11.6% | +1% (+3% cc) | Increased (per Inquiry Reply) | Increased (per Inquiry Reply) |
Gross margin | 44.05% | 45.3% | Below Joinature, declining | Below Joinature |
Profit | NP CNY 11.9 M | Underlying PBT GBP 46.4 M (−21%); reported NP GBP 27.8 M | NP increased | NP increased |
R&D intensity | 15.25% | — | — | — |
PEEK capacity (t/y) | 1,000 | 7,150 (+1,500 China JV) | 500 | n/a (fluorochemicals; DFBP-adjacent) |
Recent Developments
--



